MKS Instruments Commits to Reduce Carbon Emissions

Targets 42% reduction of combined scope 1 and 2 carbon emissions by 2030 ANDOVER, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) — MKS Instruments, Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, today announced that it has committed to reduce its combined Scope 1 Read more

Bruker Announces First 1.2 GHz NMR Installation in the United States at The Ohio State University – Funded by the U.S. National Science Foundation

Novel GHz-class NMR systems are enabling unprecedented life science and materials research in functional structural biology, drug discovery, metabolomics and cleantech research. COLUMBUS, Ohio–(BUSINESS WIRE)– Bruker Corporation, the leading provider of nuclear magnetic resonance (NMR) spectroscopy solutions for life and materials research, today announced the successful installation of a 1.2 Gigahertz (GHz) NMR system at... Read more

FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results

If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure Interim analysis results from first-of-its-kind phase III OUtMATCH study showed Xolair significantly increased the amount of peanut, milk, egg and cashew it took to cause an allergic reaction 17 million people in the U.S. have confirmed... Read more

Roche named among top three most sustainable healthcare companies in the Dow Jones Sustainability Indices

The ranking acknowledges Roche’s commitment to sustainability as an integral part of its business strategy Roche performed particularly well in innovation management, access to healthcare, greenhouse gas emissions, water management, resource efficiency and circularity, labour practice indicators and human rights This marks the 15th consecutive year that Roche has maintained its leading ranking Basel, 15... Read more

New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma

Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2 New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6 Basel, 11 December 2023 – Roche (SIX: RO, ROG;... Read more

New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A

Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favourable efficacy and safety profile of subcutaneous Hemlibra given soon after birth 1 At nearly two years median follow-up in the descriptive, single-arm study, no babies experienced spontaneous bleeds requiring treatment, and all treated bleeds were as a result of... Read more